We are pleased to let you know that as of September 1st, selinexor – under the following conditions – is now funded in Saskatchewan:

• XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Further details on the criteria can be found here: Drug Formulary (saskcancer.ca).